ATE442850T1 - Kappa-opioid-rezeptor-liganden - Google Patents
Kappa-opioid-rezeptor-ligandenInfo
- Publication number
- ATE442850T1 ATE442850T1 AT02704144T AT02704144T ATE442850T1 AT E442850 T1 ATE442850 T1 AT E442850T1 AT 02704144 T AT02704144 T AT 02704144T AT 02704144 T AT02704144 T AT 02704144T AT E442850 T1 ATE442850 T1 AT E442850T1
- Authority
- AT
- Austria
- Prior art keywords
- opioid receptor
- kappa opioid
- receptor ligands
- antagonists
- kappa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/774,566 US6559159B2 (en) | 2001-02-01 | 2001-02-01 | Kappa opioid receptor ligands |
PCT/US2002/001231 WO2002060445A1 (en) | 2001-02-01 | 2002-02-01 | Kappa opioid receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE442850T1 true ATE442850T1 (de) | 2009-10-15 |
Family
ID=25101637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02704144T ATE442850T1 (de) | 2001-02-01 | 2002-02-01 | Kappa-opioid-rezeptor-liganden |
Country Status (9)
Country | Link |
---|---|
US (1) | US6559159B2 (de) |
EP (1) | EP1363629B1 (de) |
JP (1) | JP4275945B2 (de) |
AT (1) | ATE442850T1 (de) |
AU (1) | AU2002237844B2 (de) |
CA (1) | CA2436409C (de) |
DE (1) | DE60233720D1 (de) |
ES (1) | ES2330727T3 (de) |
WO (1) | WO2002060445A1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189737B2 (en) * | 1991-08-09 | 2007-03-13 | Research Triangle Institute | Cocaine receptor binding ligands |
US6538010B1 (en) * | 2000-11-08 | 2003-03-25 | Research Triangle Institute | Compounds and methods for promoting smoking cessation |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US7056930B2 (en) * | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
ES2653568T3 (es) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
AU2005286733B2 (en) * | 2004-09-23 | 2009-11-05 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US7872023B2 (en) * | 2005-02-17 | 2011-01-18 | Research Triangle Institute | Kappa opioid receptor ligands |
US7399762B2 (en) * | 2005-04-25 | 2008-07-15 | Research Triangle Institute | Opioid receptor agonist compounds and their use in treatment of pain |
US7476679B2 (en) * | 2005-07-26 | 2009-01-13 | Research Triangle Institute | Octahydroisoquinoline compounds as opioid receptor modulators |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2258357A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
WO2008134071A1 (en) * | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
US20100210732A1 (en) * | 2005-11-02 | 2010-08-19 | Najib Babul | Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor |
US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
US8329744B2 (en) * | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2021000A2 (de) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenese mittels angiotensin-modulation |
JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5ht受容体介在性の神経新生 |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
JP2011500686A (ja) * | 2007-10-18 | 2011-01-06 | アイコ バイオテクノロジー | オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤 |
US8048895B2 (en) * | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
CA2727573A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
BRPI0921725A2 (pt) | 2008-10-30 | 2016-01-05 | Grüenthal GmbH | formas de dosagem potentes do tapentadol |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
AU2010300641B2 (en) | 2009-09-30 | 2016-03-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
JP6173693B2 (ja) | 2010-02-24 | 2017-08-02 | リサーチ・トライアングル・インスティチュート | アリールピペラジンオピオイド受容体アンタゴニスト |
CN103370058A (zh) | 2010-12-22 | 2013-10-23 | 普渡制药公司 | 包覆的抗篡改控制释放剂型 |
CN107412173A (zh) | 2010-12-23 | 2017-12-01 | 普渡制药公司 | 抗篡改固体口服剂型 |
RU2673818C2 (ru) | 2012-11-30 | 2018-11-30 | Экьюра Фармасьютикалз, Инк. | Саморегулируемое высвобождение фармацевтического ингредиента |
US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
MX2015010041A (es) | 2013-02-05 | 2015-10-30 | Purdue Pharma Lp | Formulacion farmaceuticas resistentes a la alteracion. |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
EP3122337A4 (de) | 2014-03-26 | 2017-11-08 | Sun Pharma Advanced Research Company Ltd | Missbrauchssichere feste darreichungsform mit unmittelbarer freisetzung und beschichtetem reservoir |
WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
EP3723751A4 (de) * | 2017-12-08 | 2021-07-07 | The Rockefeller University | Pyrano[3,4-b]pyrazin-kappa-opioid-rezeptorliganden zur behandlung von sucht, pruritus, schmerzen und entzündung |
EP3768679A1 (de) | 2018-03-19 | 2021-01-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vorbelastete potente opioidähnliche agonisten als verbesserte medikamente zur behandlung von chronischen und akuten schmerzen und verwendungsverfahren dafür |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4278797A (en) | 1979-03-12 | 1981-07-14 | Eli Lilly And Company | Intermediates to phenylmorphans and method of preparation thereof |
-
2001
- 2001-02-01 US US09/774,566 patent/US6559159B2/en not_active Expired - Fee Related
-
2002
- 2002-02-01 AU AU2002237844A patent/AU2002237844B2/en not_active Ceased
- 2002-02-01 WO PCT/US2002/001231 patent/WO2002060445A1/en active Application Filing
- 2002-02-01 EP EP02704144A patent/EP1363629B1/de not_active Expired - Lifetime
- 2002-02-01 AT AT02704144T patent/ATE442850T1/de not_active IP Right Cessation
- 2002-02-01 DE DE60233720T patent/DE60233720D1/de not_active Expired - Lifetime
- 2002-02-01 CA CA2436409A patent/CA2436409C/en not_active Expired - Fee Related
- 2002-02-01 ES ES02704144T patent/ES2330727T3/es not_active Expired - Lifetime
- 2002-02-01 JP JP2002560637A patent/JP4275945B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2004520383A (ja) | 2004-07-08 |
DE60233720D1 (de) | 2009-10-29 |
AU2002237844B2 (en) | 2006-03-16 |
JP4275945B2 (ja) | 2009-06-10 |
US20020143145A1 (en) | 2002-10-03 |
EP1363629A4 (de) | 2004-03-31 |
EP1363629B1 (de) | 2009-09-16 |
US6559159B2 (en) | 2003-05-06 |
CA2436409C (en) | 2010-12-07 |
WO2002060445A1 (en) | 2002-08-08 |
CA2436409A1 (en) | 2002-08-08 |
ES2330727T3 (es) | 2009-12-15 |
EP1363629A1 (de) | 2003-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE442850T1 (de) | Kappa-opioid-rezeptor-liganden | |
DE60225673D1 (de) | Kappa-opioid-rezeptor-liganden | |
AU2003299747A8 (en) | Tumor killing/tumor regression using cxcr4 antagonists | |
HK1121174A1 (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use | |
AP2004002982A0 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain. | |
AP2004003002A0 (en) | azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease. | |
EP1827468A4 (de) | Leuprolidacetat und acetylcholinesterase-hemmer oder nmda-rezeptorantagonisten zur behandlung von alzheimer-krankheit | |
MXPA03008739A (es) | Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores. | |
EP1983002A3 (de) | Tyrosinphosphorylations-Stellen und spezifische Antikörper | |
EP1848275A4 (de) | Kappa-opioidrezeptor-liganden | |
WO2008054597A3 (en) | Tyrosine phosphorylation sites | |
WO2008013948A3 (en) | Tyrosine phosphorylation sites | |
ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
DE10292400T1 (de) | Kraftstoffbehandlungsbehälter | |
WO2005044200A3 (en) | Methods and compositions for treating mcp-1 related pathologies | |
MX233159B (es) | Composiciones para tratamientos de telas. | |
SI1432417T1 (sl) | Substituirane benzimidazolne spojine in njihova uporaba za zdravljenje raka | |
WO2008013934A3 (en) | Tyrosine phosphorylation sites | |
EP1983003A3 (de) | Tyrosinphosphorylationsstellen und spezifische Antikörper | |
WO2007033140A3 (en) | Prok2 antagonists and methods of use | |
FR2871365B1 (fr) | Implant pour le traitement de la rectocele ou de la cystocele | |
IL151713A0 (en) | Monoclonal antibodies to the human ldl receptor, their production and use | |
WO2003076472A3 (en) | Neoplasm specific antibodies and uses thereof | |
NO20030593D0 (no) | Fremgangsmåter for behandling av cancer og smerten forbundet derved ved å anvende endotelinantagonister | |
EP1988103A3 (de) | Tyrosinphosphorylationsstellen und spezifische Antikörper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |